drugset
drugset / Trial / NCT01365663

Multiple Ascending Dose Study of SPC4955 in Healthy Subjects

NCT01365663 ↗

Phase 1 Completed 18 enrolled Santaris Pharma A/S
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to study safety and tolerability of SPC4955 in healthy subjects.

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject SPC4955 Unknown 0.25 mg/kg Subcutaneous
Subject SPC4955 Unknown 0.5 mg/kg Subcutaneous
Subject SPC4955 Unknown 1 mg/kg Subcutaneous
Subject SPC4955 Unknown 1.5 mg/kg Subcutaneous
Subject SPC4955 Unknown 2 mg/kg Subcutaneous

Indications

hyperlipidemia